| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | dLK1 |
| Uniprot No | P80370 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-297aa |
| 氨基酸序列 | AECFPACNPQNGFCEDDNVCRCQPGWQGPLCDQCVTSPGCLHGLCGEPGQ CICTDGWDGELCDRDVRACSSAPCANNGTCVSLDDGLYECSCAPGYSGKD CQKKDGPCVINGSPCQHGGTCVDDEGRASHASCLCPPGFSGNFCEIVANS CTPNPCENDGVCTDIGGDFRCRCPAGFIDKTCSRPVTNCASSPCQNGGTC LQHTQVSYECLCKPEFTGLTCVKKRALSPQQVTRLPNGYGLAYRLTPGVH ELPVQQPEHRILKVSMKELNKKTPVDHHHHHH |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于dLK1重组蛋白的3篇虚构参考文献示例，格式为文献名称、作者和摘要概括：
1. **"Recombinant DLK1 Protein Promotes Osteoblast Differentiation via Notch Signaling"**
*作者：Zhang Y, et al. (2020)*
**摘要**：研究通过重组表达纯化dLK1蛋白，发现其通过抑制Notch信号通路促进间充质干细胞的成骨分化，为骨再生治疗提供潜在靶点。
2. **"Structural and Functional Analysis of DLK1 in Tumor Angiogenesis"**
*作者：Chen L, et al. (2018)*
**摘要**：解析了重组dLK1蛋白的晶体结构，并证明其通过结合内皮细胞表面受体调控肿瘤血管生成，提示其作为癌症治疗新策略的可能性。
3. **"DLK1 Recombinant Protein Enhances Adipose Tissue Regeneration in Metabolic Disorders"**
*作者：Wang H, et al. (2021)*
**摘要**：利用重组dLK1蛋白处理小鼠模型，发现其通过激活Wnt/β-catenin通路改善脂肪组织代谢功能，为肥胖相关疾病提供干预方向。
(注：以上文献为示例性内容，实际研究中请参考真实数据库如PubMed)
**Background of dLK1 Recombinant Protein**
The dLK1 (Delta-like 1 homolog) protein, also known as Preadipocyte Factor 1 (Pref-1), is a transmembrane protein belonging to the epidermal growth factor (EGF)-like repeat superfamily. It functions as a critical regulator of cellular differentiation, particularly in adipogenesis, stem cell maintenance, and embryonic development. Initially identified for its role in inhibiting adipocyte differentiation, dLK1 interacts with the Notch signaling pathway, modulating cell fate decisions through paracrine or juxtacrine mechanisms. Its extracellular domain, containing six EGF-like repeats, is proteolytically cleaved to release a soluble form, which retains biological activity and serves as a biomarker or therapeutic agent.
Recombinant dLK1 protein is engineered to mimic this soluble isoform, often produced using expression systems like *E. coli* or mammalian cells. It enables researchers to study dLK1’s function in vitro and in vivo, such as its effects on stem cell self-renewal, tissue regeneration, or cancer progression. Dysregulation of dLK1 is linked to metabolic disorders (e.g., obesity, diabetes), certain cancers (e.g., hepatocellular carcinoma), and developmental abnormalities, highlighting its biomedical relevance.
The recombinant protein’s applications extend to drug discovery, diagnostic assays, and regenerative medicine. For example, it is used to explore therapeutic strategies targeting dLK1-overexpressing tumors or to modulate adipogenesis in metabolic disease models. Ongoing research also investigates its role in neuronal development and immune regulation, underscoring its multifaceted biological significance.
×
